← Back to Search

Descartes-08 for Multiple Myeloma

Phase 2
Research Sponsored by Cartesian Therapeutics
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Patients must be 18 years of age or older at the time of enrollment
High-risk multiple myeloma patients who complete pre-transplant induction treatment anti-myeloma drug combination (minimum 2 drugs).
Screening 3 weeks
Treatment Varies
Follow Up 2 years
Awards & highlights
No Placebo-Only Group

Study Summary

This trial is testing a new treatment for myeloma patients who still have some disease remaining after induction therapy. The goal is to see if this new treatment can help these patients achieve a complete response.

Who is the study for?
This trial is for adults over 18 with high-risk multiple myeloma who still have signs of the disease after initial drug treatment. It's not open to pregnant or breastfeeding individuals, nor those with uncontrolled infections.Check my eligibility
What is being tested?
The trial is testing Descartes-08 as a consolidation treatment to see if it can fully clear any remaining myeloma cells in patients who've already undergone induction therapy.See study design
What are the potential side effects?
Potential side effects of Descartes-08 are not specified here, but similar treatments may cause immune reactions, fatigue, nausea, and increased risk of infection.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
I am 18 years old or older.
I have high-risk multiple myeloma and finished a treatment with at least 2 drugs before a stem cell transplant.


Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~2 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and 2 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Rate of stringent complete response

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: Descartes 08Experimental Treatment1 Intervention

Find a Location

Who is running the clinical trial?

Cartesian TherapeuticsLead Sponsor
7 Previous Clinical Trials
177 Total Patients Enrolled
4 Trials studying Multiple Myeloma
87 Patients Enrolled for Multiple Myeloma

Media Library

Descartes 08 Clinical Trial Eligibility Overview. Trial Name: NCT04816526 — Phase 2
Multiple Myeloma Research Study Groups: Descartes 08
Multiple Myeloma Clinical Trial 2023: Descartes 08 Highlights & Side Effects. Trial Name: NCT04816526 — Phase 2
Descartes 08 2023 Treatment Timeline for Medical Study. Trial Name: NCT04816526 — Phase 2

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

How can people sign up for this opportunity?

"That is correct. The information on clinicaltrials.gov indicates that the trial, which was first advertised on December 1st 2021, is still recruiting patients. They need 30 more participants and have 2 sites where people can enroll."

Answered by AI

What is the Descartes 08 drug's official standing with the FDA?

"Because a Phase 2 trial only provides evidence of safety and not efficacy, our team has given Descartes 08 a score of 2."

Answered by AI

How many individuals are included in this experiment?

"Yes, this information can be found on clinicaltrials.gov. The trial was posted on December 1st 2021 and updated April 4th 2022. They are looking for 30 participants total at 2 sites."

Answered by AI
~9 spots leftby Feb 2025